Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1981-8-10
|
| pubmed:abstractText |
With the purpose of investigating effectivity and acceptability of an oral contraceptive containing micronized natural estrogens (estradiol-17 beta 4 mg + estriol 2 mg/norethisterone acetate 3 mg per tablet) versus a contraceptive containing artificial estrogen (ethinyl estradiol 50 micrograms/ norethisterone acetate 3 mg per tablet), a controlled double-blind investigation was performed in 111 young women. The investigation was designed for 12 cycles. The tablets were given consecutively for 3 weeks with 1 week's interruption. In the natural estrogen group 57 women completed 504 cycles, in the artificial estrogen group 54 women completed 510 cycles (Table 1). No pregnancies occurred. There were highly significantly more terminations due to bleeding irregularities (p less than 0.001), and highly significantly more spotting (p less than 0.001), breakthrough (p less than 0.001) and amenorrhea (p less than 0.001) episodes in the natural estrogen group (Tables II and III). Bleeding irregularities on natural estrogens did not subside during the trial (Table IV). There were a few more psychiatric and CNS symptoms on natural estrogen (p less than 0.05), but other side effects did not differ between the two preparations (Table V). Blood pressure and weight did not vary significantly. Despite documented metabolic advantages, the natural estrogen tablet investigated was not found to be clinically acceptable for general usage because of the high incidence of bleeding irregularities. It is conceivable that a change of the estrogen/gestagen ratio, using a variable 3-week schedule, would reduce the number of bleeding irregularities.
|
| pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/ACNE,
http://linkedlifedata.com/resource/pubmed/keyword/Abdominal Cramps,
http://linkedlifedata.com/resource/pubmed/keyword/Amenorrhea,
http://linkedlifedata.com/resource/pubmed/keyword/Appetite Alterations,
http://linkedlifedata.com/resource/pubmed/keyword/BLOOD PRESSURE,
http://linkedlifedata.com/resource/pubmed/keyword/Contraception,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents, Estrogen,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents, Female,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Methods,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Methods--side effects,
http://linkedlifedata.com/resource/pubmed/keyword/Control Groups,
http://linkedlifedata.com/resource/pubmed/keyword/DYSMENORRHEA,
http://linkedlifedata.com/resource/pubmed/keyword/Decreased Libido,
http://linkedlifedata.com/resource/pubmed/keyword/Depression,
http://linkedlifedata.com/resource/pubmed/keyword/Dizziness,
http://linkedlifedata.com/resource/pubmed/keyword/Double-blind Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Dropouts,
http://linkedlifedata.com/resource/pubmed/keyword/EDEMA,
http://linkedlifedata.com/resource/pubmed/keyword/FATIGUE,
http://linkedlifedata.com/resource/pubmed/keyword/Family Planning,
http://linkedlifedata.com/resource/pubmed/keyword/HEADACHE,
http://linkedlifedata.com/resource/pubmed/keyword/Infections,
http://linkedlifedata.com/resource/pubmed/keyword/METRORRHAGIA,
http://linkedlifedata.com/resource/pubmed/keyword/Mammary Gland Effects,
http://linkedlifedata.com/resource/pubmed/keyword/NAUSEA,
http://linkedlifedata.com/resource/pubmed/keyword/NERVOUSNESS,
http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives, Combined,
http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives--side effects,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Vomiting
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Contraceptives, Oral,
http://linkedlifedata.com/resource/pubmed/chemical/Contraceptives, Oral, Combined,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Estriol,
http://linkedlifedata.com/resource/pubmed/chemical/Ethinyl Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Norethindrone
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0001-6349
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
60
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
203-6
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:otherAbstract |
PIP: With the purpose of investigating effectivity and acceptability of an oral contraceptive containing micronized natural estrogens (estradiol-17beta 4 mg + estriol 2 mg/norethisterone acetate 3 mg/tablet) versus a contraceptive containing artificial estrogen (ethinyl estradiol 50 mcg/norethisterone acetate 3mg/tablet), a controlled double-blind investigation was performed in 111 young women. The investigation was designed for 12 cycles. The tablets were given consecutively for 3 weeks with 1 week's interruption. In the natural estrogen group, 57 women completed 504 cycles; in the artificial estrogen group 54 women completed 510 cycles. No pregnancies occurred. There were highly significantly more terminations due to bleeding irregularities (P 0.001), and highly significantly more spotting (p 0.001), breakthrough (p 0.001) and amenorrhea (p 0.001) episodes in the natural estrogen group. Bleeding irregularities on natural estrogens did not subside during the trial. There were a few more psychiatric and central nervous system symptoms on natural estrogen (p 0.05), but other side effects did not differ between the 2 preparations. Blood pressure and weight did not vary significantly. Despite documented metabolic advantages, the natural estrogen tablet investigated was not found to be clinically acceptable for general usage because of the high incidence of bleeding irregularities. It is conceivable that a change of the estrogen/gestagen ratio, using a variable 3-week schedule, would reduce the number of bleeding irregularities.
|
| pubmed:meshHeading |
pubmed-meshheading:7018165-Adolescent,
pubmed-meshheading:7018165-Adult,
pubmed-meshheading:7018165-Clinical Trials as Topic,
pubmed-meshheading:7018165-Contraceptives, Oral,
pubmed-meshheading:7018165-Contraceptives, Oral, Combined,
pubmed-meshheading:7018165-Double-Blind Method,
pubmed-meshheading:7018165-Estradiol,
pubmed-meshheading:7018165-Estriol,
pubmed-meshheading:7018165-Ethinyl Estradiol,
pubmed-meshheading:7018165-Female,
pubmed-meshheading:7018165-Humans,
pubmed-meshheading:7018165-Lipids,
pubmed-meshheading:7018165-Menstruation Disturbances,
pubmed-meshheading:7018165-Norethindrone
|
| pubmed:year |
1981
|
| pubmed:articleTitle |
Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|